Pirenzepine dihydrochloride

Research use only, not for human use.

An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function.

An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as climetidine and panitidine.(In Vitro):Pirenzepine (100-140 μg/mL; 24 h) inhibits PC-3 cell proliferation activity.Pirenzepine (110 μg/mL; 24 h) inhibits prostate and lung cancer cell migration.Pirenzepine (100-130 μg/mL; 0-24 h) inhibits the expression of GLI1 in PC-3 cells.(In Vivo):Pirenzepine (intraperitoneal injection; 0.3 mg/kg; once) treatment shows beneficial effects in lipopolysaccharide-induced septic shock.

Pirenzepine (100-140 μg/mL; 24 h) inhibits PC-3 cell proliferation activity.Pirenzepine (110 μg/mL; 24 h) inhibits prostate and lung cancer cell migration.Pirenzepine (100-130 μg/mL; 0-24 h) inhibits the expression of GLI1 in PC-3 cells. Cell Proliferation Assay Cell Line:PC-3 cells Concentration:100-140 μg/mL Incubation Time:24 hours Result:Inhibited PC-3 cell proliferation in a concentration-dependent manner.Cell Migration Assay Cell Line:PC-3 and A549 cells Concentration:110 μg/mL Incubation Time:24 hours Result:Inhibited the migration of PC-3 and A549 cell lines (P=0.014).Cell Migration Assay Cell Line:PC-3 cells Concentration:110 μg/mL Incubation Time:0-24 hours Result:Inhibited the expression of GLI1 and PTCH1.RT-PCR Cell Line:PC-3 cells Concentration:100-130 μg/mL Incubation Time:24 hours Result:Suppressed GLI1 mRNA expression in PC-3 cells. Increased PTCH1 mRNA level but not reach statistical significance.

Pirenzepine (intraperitoneal injection; 0.3?mg/kg; once) treatment shows beneficial effects in lipopolysaccharide-induced septic shock. Animal Model:Male C57BL/6 mice with experimental endotoxemia Dosage:0.3?mg/kg Administration:Intraperitoneal injection; 0.3?mg/kg; once Result:Improved survival rate of LPS-induced septic shock.Relieved LPS-induced pulmonary and hepatic injury.Reduced the expression of SOCS3 at mRNA level.

——

Endocrinology/Hormones

AChR

mAChR

Neurological Disease

——

29868-97-1

424.32

C19H21N5O2·2HCl

>98% (HPLC)

Water: 100 mM

Cl.Cl.CN1CCN(CC(=O)N2C3=CC=CC=C3C(=O)NC3=C2N=CC=C3)CC1

——

(-20℃)

With Ice Pack

≥ 2 years